(Reuters) – German drugmaker BioNTech SE’s executive on Wednesday said the interval between the second and third doses of its COVID-19 vaccine can be reduced to at least three months to enable better protection against the Omicron variant in the winter season.
Chief Executive Officer Ugur Sahin said new data would prompt a discussion about bringing the third shot of its currently available vaccine forward. “We believe this is the right way to go,” he said.
“It is very clear that our vaccine for the Omicron variant should be a three-dose vaccine,” he added during a press call.
Source: Read Full Article
